GTx enrolls first patient in Phase 2 clinical trial of enobosarm in ER+/AR+ breast cancer
Enobosarm, a selective androgen receptor modulator (SARM), is the Company’s lead product candidate. GTx executive chairman Robert Wills said: "Additional endocrine directed therapies are needed for the treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.